Filing Details
- Accession Number:
- 0001415889-25-003822
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2025-02-12 21:27:02
- Reporting Period:
- 2025-02-11
- Filing Date:
- 2025-02-12
- Accepted Time:
- 2025-02-12 21:27:02
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1438533 | Travere Therapeutics Inc. | TVTX | Pharmaceutical Preparations (2834) | 262383102 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1882909 | Sandra Calvin | C/O Travere Therapeutics, Inc. 3611 Valley Centre Drive, Suite 300 San Diego CA 92130 | Svp, Chief Accounting Officer | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2025-02-11 | 10,000 | $16.23 | 73,654 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2025-02-11 | 10,000 | $25.00 | 63,654 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2025-02-11 | 10,000 | $17.44 | 73,654 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2025-02-11 | 10,000 | $25.00 | 63,654 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2025-02-11 | 10,000 | $17.96 | 73,654 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2025-02-11 | 10,000 | $25.00 | 63,654 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2025-02-11 | 15,000 | $15.46 | 78,654 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2025-02-11 | 15,000 | $25.00 | 63,654 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2025-02-11 | 9,244 | $25.00 | 54,410 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Employee stock option (right to buy) | Disposition | 2025-02-11 | 10,000 | $0.00 | 10,000 | $16.23 |
| Common Stock | Employee stock option (right to buy) | Disposition | 2025-02-11 | 10,000 | $0.00 | 10,000 | $17.44 |
| Common Stock | Employee stock option (right to buy) | Disposition | 2025-02-11 | 10,000 | $0.00 | 10,000 | $17.96 |
| Common Stock | Employee stock option (right to buy) | Disposition | 2025-02-11 | 15,000 | $0.00 | 15,000 | $15.46 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2026-05-19 | No | 4 | M | Direct | |
| 0 | 2027-05-17 | No | 4 | M | Direct | |
| 0 | 2029-05-09 | No | 4 | M | Direct | |
| 0 | 2030-01-31 | No | 4 | M | Direct |
Footnotes
- This sale was made pursuant to a written plan adopted on September 9, 2024, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option grant to the Reporting Person on May 19, 2016 with an expiration date of May 19, 2026.
- This sale was made pursuant to a written plan adopted on September 9, 2024, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option grant to the Reporting Person on May 17, 2017 with an expiration date of May 17, 2027.
- This sale was made pursuant to a written plan adopted on September 9, 2024, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option grant to the Reporting Person on May 9, 2019 with an expiration date of May 9, 2029.
- This sale was made pursuant to a written plan adopted on September 9, 2024, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option grant to the Reporting Person on January 31, 2020 with an expiration date of January 31, 2030.
- This sale was made pursuant to a written plan adopted on September 9, 2024, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.
- The stock option is fully vested and exercisable.
Billionaire Hedge Funds
